Practice Guidelines Initiative

Chamberlain MC, Sloan A, Vrionis F (2005) Systematic review of the diagnosis and management of malignant exhadural spine cord compression The Cancer Care Ontario Practice Guidelines Initiative s Neuro-Oncology Disease Site Group. J Clin Oncol 23 7750-7751 author reply 7751-7752. 

Program in Evidence-Based Care and the Cancer Care Ontario Practice Guidelines Initiative ccopgi/index.html for numerous malignancies and use guidelines for supportive care agents. 

Cancer Care Ontario Practice Guidelines Initiative (CCOPGI)... 

Either UFH or LMWH should be administered to patients with NSTE ACS. Therapy should be continued for up to 48 hours or until the end of the angiography or PCI procedure. In patients initiating warfarin therapy, UFH or LMWHs should be continued until the International Normalized Ratio (INR) with warfarin is in the therapeutic range for 2 consecutive days. The addition of UFH to aspirin reduces the rate of death or MI in patients with NSTE ACS.47 Enoxaparin was mentioned as preferred over UFH in the 2002 ACC/AHA clinical practice guidelines, as two large clinical trials found a reduction in the combined endpoint of death, MI, or need for PCI in patients... 

Eschbach J, DeOreo PB, Adamson J, et al. NKF-K/DOQI Clinical Practice Guidelines, National Kidney Foundation, Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) 2000, 2005 available from www.kidney.org/professionals/kdoqi/ guidelines updates/doqi uptoc.html an. 

Specific guidance on the initial quality control procedure for a testing laboratory is available as an PDA addendum. The addendum and other practical guidelines are available from Associates of Cape Cod, Inc. 

Modified from National Kidney Foundation Document. CHnical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002 39 81-246. 

Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents Evaluation, classification, and stratification. Pediatrics 2003 111 1416-1421. 

The AASLD practice guidelines recommend that diuretic therapy be initiated with the combination of spironolactone and furosemide. Spironolactone alone was commonly recommended for initial therapy, but clinical trials have demonstrated a 14-day delay in the onset of action, as well as the development hyperkalemia when spironolactone is used alone. Administering spironolactone in single daily doses is justified based on its pharmacokinetics and helps to improve patient compliance. If tense ascites is present, paracentesis... 

Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) is the most widely accepted diagnostic reference. It, along with the American Psychiatric Association (APA) Practice Guidelines for the Psychiatric Evaluation of Adults, provides the clinician a standardized approach forthe initial assessment and followup of patients with mental illness. 

Costa PT Jr., Williams TF, Somerfield M, et al. Recognition and Initial Assessment of Alzheimer s Disease and Related Dementias. Clinical Practice Guideline No. 19. Rockville, MD, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996. AHCPR No. 97-0702. 

Clinical practice guidelines to guide the appropriate use of erythropoietic agents have been developed (Fig. 124-14). The first step is to evaluate the underlying cause of the anemia and initiate specific therapy as indicated. For example, patients with iron deficiency anemia should receive iron supplementation. Patients with chronic bleeding or hemolysis should not receive erythropoietic therapy, as... 

Caution Doses listed for patients with body weight less dian 50 kg cannot be used as initial starting doses in babies less dian 6 mondis of age. Consult die Clinical Practice Guideline for Acute Pain Management Operative or Medical Procedures and Trauma section on management of pain in neonates for recommendations. 

Thalidomide (thalomid) is used to treat patients with relapsed and refractory MM, as well as early stage disease. The National Comprehensive Cancer Network (NCCN www.nccn.org) Clinical Practice Guidelines for Multiple Myeloma includes thalidomide as an option for salvage therapy in patients with relapsed or refractory MM, or as initial therapy in combination with dexamethasone for patients with advanced myeloma. Thalidomide is also in clinical trials for use in treating a variety of solid tumors and myelodysplasias. 

---